Maťoška V - Search Results

1

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.

Tomek A, Maťoška V, Kolářová T, Neumann J, Srámek M, Sarbochová I, Táborský L, Bojar M, Goetz P, Serebruany VL. Tomek A, et al. Among authors: matoska v. Cardiology. 2013;125(3):182-91. doi: 10.1159/000350407. Epub 2013 Jun 12. Cardiology. 2013. PMID: 23774101

2

Can ataxin-2 be down-regulated by allele-specific de novo DNA methylation in SCA2 patients?

Bauer PO, Zumrova A, Matoska V, Mitsui K, Goetz P. Bauer PO, et al. Among authors: matoska v. Med Hypotheses. 2004;63(6):1018-23. doi: 10.1016/j.mehy.2004.03.046. Med Hypotheses. 2004. PMID: 15504570

3

Fluorescent multiplex PCR--fast method for autosomal dominant spinocerebellar ataxias screening.

Bauer PO, Kotliarova SE, Matoska V, Musova Z, Hedvicakova P, Boday A, Tomek A, Nukina N, Goetz P. Bauer PO, et al. Among authors: matoska v. Genetika. 2005 Jun;41(6):830-7. Genetika. 2005. PMID: 16080609

4

Genotype/phenotype correlation in a SCA1 family: anticipation without CAG expansion.

Bauer PO, Matoska V, Zumrova A, Boday A, Doi H, Marikova T, Goetz P. Bauer PO, et al. Among authors: matoska v. J Appl Genet. 2005;46(3):325-8. J Appl Genet. 2005. PMID: 16110192

5

Absence of spinocerebellar ataxia type 3/Machado-Joseph disease within ataxic patients in the Czech population.

Bauer PO, Zumrova A, Matoska V, Marikova T, Krilova S, Boday A, Singh B, Goetz P. Bauer PO, et al. Among authors: matoska v. Eur J Neurol. 2005 Nov;12(11):851-7. doi: 10.1111/j.1468-1331.2005.01090.x. Eur J Neurol. 2005. PMID: 16241973

6

[Application of warfarin pharmacogenetics].

Tomek A, Mat'oska V, Kumstýrfová T, Táborský L. Tomek A, et al. Vnitr Lek. 2009 Jun;55(6):565-9. Vnitr Lek. 2009. PMID: 19662888 Review. Czech.

7

Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerations.

Tomek A, Matoska V, Eisert C, Serebruany VL. Tomek A, et al. Among authors: matoska v. Am J Ther. 2011 May;18(3):e55-66. doi: 10.1097/MJT.0b013e3181cea0cd. Am J Ther. 2011. PMID: 20335792 Review.

8

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.

Libertinova J, Meluzinova E, Tomek A, Horakova D, Kovarova I, Matoska V, Kumstyrova S, Zajac M, Hyncicova E, Liskova P, Houzvickova E, Martinkovic L, Bojar M, Havrdova E, Marusic P. Libertinova J, et al. Among authors: matoska v. PLoS One. 2017 Jan 12;12(1):e0169957. doi: 10.1371/journal.pone.0169957. eCollection 2017. PLoS One. 2017. PMID: 28081207 Free PMC article. Clinical Trial.

9

MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.

Libertinova J, Meluzinova E, Matoska V, Zajac M, Kovarova I, Havrdova E, Horakova D, Tomek A, Marusic P, Bojar M. Libertinova J, et al. Among authors: matoska v. Brain Behav. 2017 Feb 9;7(3):e00644. doi: 10.1002/brb3.644. eCollection 2017 Mar. Brain Behav. 2017. PMID: 28293479 Free PMC article.

10

Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.

Tomek A, Matʼoška V, Frýdmanová A, Magerová H, Šrámek M, Paulasova-Schwabová J, Růžičková T, Janský P, Šarbochová I, Hadačová I, Kaplan V, Lacinová Z, Táborský L, Serebruany V. Tomek A, et al. Among authors: matoska v. Am J Ther. 2018 Mar/Apr;25(2):e202-e212. doi: 10.1097/MJT.0000000000000416. Am J Ther. 2018. PMID: 29509167

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters